Access Pharmaceuticals, Inc. is an emerging pharmaceutical company developing unique polymer linked cytotoxics for use in the treatment of cancer and other diseases states.The Company also has other advanced drug delivery technologies including vitamin-mediated targeted delivery and oral care drug delivery. On October 2005, Access sold its oral care and dermatology business unit to Uluru, Inc to focus on its technologies in oncology and oral drug delivery. The products and technologies sold to Uluru include amlexanox 5% paste (marketed under the trade names Aphthasol® and Aptheal®), OraDiscTM, Zindaclin® and Residerm® and all of Access assets related to these products.

Acquired Companies: MacroChem Corp., Somanta Pharmaceuticals, Inc.